

(Note)

This document is an excerpt of translation of the original Japanese language document and has been prepared solely for reference purposes. In the event of any discrepancy between this English translation and the original Japanese language document, the original Japanese language document shall prevail in all respects.

## Consolidated Financial Results for the Nine Months Ended December 31, 2025 (IFRS)

February 2, 2026

Company name: CUC Inc.  
Stock exchange: Tokyo Stock Exchange  
Code number: 9158  
URL: <https://www.cuc-jpn.com/en/>  
Representative: Keita Hamaguchi, Representative Director  
Contact: Yusuke Ohashi, Executive Officer Phone: +81-3-5005-0808  
Availability of supplementary materials on financial results: Available  
Schedule of financial results briefing session: Scheduled

(Amounts are rounded to the nearest million yen)

### 1. Consolidated financial results for the nine months ended December 31, 2025

#### (1) Consolidated operating results

(% indicates changes from the previous corresponding period.)

|                                     | Revenue     |      | Operating profit |        | Profit before taxes |        | Net income  |        | Net income attributable to CUC shareholders |        | Total comprehensive income |        |
|-------------------------------------|-------------|------|------------------|--------|---------------------|--------|-------------|--------|---|--------|----------------------------|--------|
|                                     | Million yen | %    | Million yen      | %      | Million yen         | %      | Million yen | %      | Million yen                                 | %      | Million yen                | %      |
| Nine months ended December 31, 2025 | 40,170      | 16.2 | 3,181            | (30.5) | 2,699               | (40.5) | 1,371       | (49.6) | 1,433                                       | (48.3) | 1,781                      | (25.9) |
| December 31, 2024                   | 34,562      | 47.9 | 4,576            | 74.6   | 4,536               | 86.5   | 2,722       | 82.8   | 2,770                                       | 84.7   | 2,404                      | 92.3   |

|                                     | Basic earnings per share |  | Diluted earnings per share |  |
|-------------------------------------|--------------------------|--|----------------------------|--|
|                                     | Yen                      |  | Yen                        |  |
| Nine months ended December 31, 2025 | 48.87                    |  | 48.87                      |  |
| December 31, 2024                   | 94.50                    |  | 94.50                      |  |

#### (2) Consolidated financial position

|                         | Total assets | Total equity | Equity attributable to CUC shareholders | Ratio of equity attributable to CUC shareholders |
|-------------------------|--------------|--------------|---|--|
|                         | Million yen  | Million yen  | Million yen                             | %  |
| As of December 31, 2025 | 95,984       | 32,194       | 31,586                                  | 32.9   |
| As of March 31, 2025    | 85,167       | 30,286       | 29,678                                  | 34.8   |

### 2. Dividends

|  | Dividends per share |                |               |                |       |
|--|---------------------|----------------|---------------|----------------|-------|
|  | First quarter       | Second quarter | Third quarter | Fourth quarter | Total |
|  | Yen                 | Yen            | Yen           | Yen            | Yen   |
| Fiscal year ended March 31, 2025             | -                   | 0.00           | -             | 0.00           | 0.00  |
| Fiscal year ending March 31, 2026            | -                   | 0.00           | -             |                |       |
| Fiscal year ending March 31, 2026 (Forecast) |                     |                |               | 0.00           | 0.00  |

(Note) Revision to the forecast for dividends announced most recently: None

3. Consolidated financial results forecast for the fiscal year ending March 31, 2026 (April 1, 2025 to March 31, 2026)

(% indicates changes from the previous corresponding period.)

|           | Revenue     |      | Operating profit |     | Profit before taxes |       | Net income  |       | Net income attributable to CUC shareholders |       | Basic earnings per share |
|-----------|-------------|------|------------------|-----|---------------------|-------|-------------|-------|---|-------|--------------------------|
|           | Million yen | %    | Million yen      | %   | Million yen         | %     | Million yen | %     | Million yen                                 | %     | Yen                      |
| Full-year | 58,250      | 23.8 | 5,500            | 2.9 | 5,000               | (4.7) | 2,880       | (6.4) | 2,880                                       | (8.0) | 98.24                    |

(Note) Revision to the financial results forecast announced most recently: None

\* Notes:

(1) Significant changes in the scope of consolidation during the period: None

(2) Changes in accounting policies and accounting estimates

- 1) Changes in accounting policies required by IFRS: None
- 2) Changes in accounting policies other than item 1) above: None
- 3) Changes in accounting estimates: None

(3) Total number of issued shares (common shares)

1) Total number of issued shares at the end of the period (including treasury shares):

December 31, 2025: 29,990,400 shares

March 31, 2025: 29,990,400 shares

2) Total number of treasury shares at the end of the period:

December 31, 2025: 675,091 shares

March 31, 2025: 675,091 shares

3) Average number of shares during the period:

Nine months ended December 31, 2025: 29,315,309 shares

Nine months ended December 31, 2024: 29,315,328 shares

\* Quarterly consolidated financial statements are outside the scope of review by certified public accountants or an audit firm.

\* Explanation of the proper use of financial results forecast and other notes

The forward-looking statements in this report including the forecast of financial results are based on the information that is currently available, as well as certain assumptions that are deemed to be reasonable by CUC. These forward-looking statements do not represent any guarantee of achievement. Therefore, there might be cases in which actual results differ materially from the forecast due to various factors.

## 1. Qualitative information on financial results

### (1) Explanation of operating results

The group's mission is "Creating Hope through Healthcare". Under this mission, CUC group provides various services, aiming to create an environment where patient-centered healthcare is provided for as many people as possible, to develop a workplace required by local communities in which all healthcare workers are proud and motivated, and to build sound and sustainable society by solving healthcare issues.

Medical Institution segment mainly provides comprehensive management support services to domestic medical institutions such as strategic and business management support, marketing support, HR/recruiting support, IT support, accounting support, and general affairs support. It also provides strategic support for M&A transactions, PMIs hospital bed conversion and the launch of new clinics. Those medical institutions include hospitals, in-home care clinics, dialysis clinics and outpatient clinics in Japan. The segment operates podiatry and varicose vein clinics in the United States and provides management support services in Southeast Asia.

Hospice segment provides nursing and care services for patients with cancer and intractable diseases who live in hospice facilities, prioritizing the quality of services. The segment has increased the number of patients at existing hospices and launched hospices in the area which is in lack of terminal care.

In-home Nursing segment provides nursing services for patients at their home, prioritizing the quality of services. The segment has increased the number of users for existing in-home nursing stations and launched in-home nursing stations in new areas.

Medical Care Residence segment operates nursing homes and provides regular on-demand in-home care and in-home nursing care for patients in facilities and day care services for rehabilitation, prioritizing the quality of services. The segment aims to improve its occupancy rate in the existing facilities, open new facilities in areas which has high demand for care services and accept patients with high medical and care dependencies.

The following table presents operating results for the nine months ended December 31, 2025 and the previous corresponding period. Medical Care Residence was established in the third quarter of the previous fiscal year, resulting in significant year-on-year fluctuations.

The definition of EBITDA is as follows.

EBITDA = operating profit + depreciation and amortization expenses ± other income and expenses

### Consolidated operating results

(Million yen)

|  | Nine months ended<br>December 31, 2024 | Nine months ended<br>December 31, 2025 | Changes |         |
|--|--|--|---------|---------|
| Revenue  | 34,562                                 | 40,170                                 | +5,608  | +16.2%  |
| Operating profit                               | 4,576                                  | 3,181                                  | (1,394) | (30.5%) |
| Profit before taxes                            | 4,536                                  | 2,699                                  | (1,837) | (40.5%) |
| Net income attributable to CUC<br>shareholders | 2,770                                  | 1,433                                  | (1,338) | (48.3%) |
| EBITDA   | 6,603                                  | 6,129                                  | (474)   | (7.2%)  |

Operating results by segment

(Million yen)

|                           |                | Nine months ended<br>December 31, 2024 | Nine months ended<br>December 31, 2025 | Changes |         |
|---------------------------|----------------|--|--|---------|---------|
| Medical<br>Institution    | Revenue        | 13,425                                 | 12,646                                 | (778)   | (5.8%)  |
|                           | Segment profit | 2,992                                  | 2,424                                  | (568)   | (19.0%) |
|                           | EBITDA         | 3,812                                  | 2,861                                  | (952)   | (25.0%) |
| Hospice                   | Revenue        | 10,215                                 | 12,282                                 | +2,067  | +20.2%  |
|                           | Segment profit | 1,054                                  | 523                                    | (530)   | (50.3%) |
|                           | EBITDA         | 1,759                                  | 1,526                                  | (233)   | (13.2%) |
| In-home<br>Nursing        | Revenue        | 9,254                                  | 9,775                                  | +522    | +5.6%   |
|                           | Segment profit | 993                                    | 1,103                                  | +110    | +11.1%  |
|                           | EBITDA         | 1,345                                  | 1,399                                  | +54     | +4.0%   |
| Medical Care<br>Residence | Revenue        | 1,798                                  | 5,732                                  | +3,934  | +218.8% |
|                           | Segment profit | 116                                    | (149)                                  | (265)   | -       |
|                           | EBITDA         | 312                                    | 1,046                                  | +734    | +235.3% |
| Others                    | Revenue        | 102                                    | 71                                     | (31)    | (30.2%) |
|                           | Segment profit | 56                                     | (16)                                   | (72)    | -       |
|                           | EBITDA         | 10                                     | (12)                                   | (22)    | -       |
| Adjustment                | Revenue        | (231)                                  | (336)                                  | (105)   | -       |
|                           | Segment profit | (635)                                  | (703)                                  | (68)    | -       |
| Total                     | Revenue        | 34,562                                 | 40,170                                 | +5,608  | +16.2%  |
|                           | Segment profit | 4,576                                  | 3,181                                  | (1,394) | (30.5%) |
|                           | EBITDA         | 6,603                                  | 6,129                                  | (474)   | (7.2%)  |

1) Medical Institution

Revenue, operating profit and EBITDA from the segment for the nine months ended December 31, 2025 amounted to 12,646 million yen (down 5.8% year on year), 2,424 million yen (down 19.0% year on year) and 2,861 million yen (down 25.0% year on year) respectively. This is primarily due to a decrease in domestic revenue, which was attributable to a temporary slowdown as some of the client medical institutions experienced a decline in their profitability in the first half of this fiscal year, as well as a reactionary drop following the concentration of M&A advisory fees in the first quarter of the previous fiscal year. Reflecting the improved performance of client medical institutions, we began a phased normalization of monthly fees in the third quarter. However, the impact of earlier fee reductions was not fully offset during the first nine months, despite the recovery trend in the second half. While roll-up M&A in the US podiatry business performed steadily, overseas revenue decreased overall due to lower collections of past receivables year-on-year and the restructuring of unprofitable clinics.

## 2) Hospice

Revenue from the segment for the nine months ended December 31, 2025 amounted to 12,282 million yen (up 20.2% year on year) primarily due to the steady contribution of newly opened facilities and an increase in occupancy rates of existing hospice facilities.

Operating profit and EBITDA from the segment amounted to 523 million yen (down 50.3% year on year) and 1,526 million yen (down 13.2% year on year) respectively. This is primarily due to the initial losses incurred from the launch of new facilities and a decline in revenue per patient at certain existing facilities.

## 3) In-home Nursing

Total care hours (Note) for the nine months ended December 31, 2025 were 962 thousand hours (up 4.4% year on year) due to an increase in the number of users. As a result, revenue from the segment for the nine months ended December 31, 2025 amounted to 9,775 million yen (up 5.6% year on year).

Operating profit and EBITDA from the segment amounted to 1,103 million yen (up 11.1% year on year) and 1,399 million yen (up 4.0% year on year) respectively. This is primarily driven by an increase in the number of users, despite initial losses associated with opening new stations..

(Note) Total number of hours of services provided by the segment's nurses and therapists to users. Therapists mean physical therapists, occupational therapists, and speech therapists.

## 4) Medical Care Residence

CUC acquired Noah Konzer in the third quarter of the previous fiscal year and established this new segment. Revenue, operating loss and EBITDA from the segment for the nine months ended December 31, 2025 amounted to 5,732 million yen (up 218.8% year on year), 149 million yen (operating profit of 116 million yen for the previous corresponding period) and 1,046 million yen (up 235.3% year on year) respectively. This is primarily due to steady growth in sales of the medication support system "Fukuyakkun" and increased revenue from nursing care medical fees, which was partially offset by temporary capacity constraints due to facility renovations to establish hospice floors.

As a result of the above, the group recorded revenue of 40,170 million yen (up 16.2% year on year), operating profit of 3,181 million yen (down 30.5% year on year), EBITDA of 6,129 million yen (down 7.2% year on year).

With the reactionary fall from foreign exchange gains of 360 million yen related to the repayment of loans to the U.S. subsidiary recorded in the previous fiscal year, the group recorded profit before taxes of 2,699 million yen (down 40.5% year on year) and net income attributable to CUC shareholders of 1,433 million yen (down 48.3% year on year).

## (2) Explanation of financial position

Total assets as of December 31, 2025 amounted to 95,984 million yen, an increase of 10,817 million yen compared with the balance as of March 31, 2025. Current assets as of December 31, 2025 amounted to 27,696 million yen, an increase of 7,175 million yen compared with the balance as of March 31, 2025. This was primarily due to an increase in cash and cash equivalents of 5,736 million yen mainly arising from proceeds from long-term borrowings designated for financing the domestic hospice construction and overseas business operations. Non-current assets as of December 31, 2025 amounted to 68,288 million yen, an increase of 3,641 million yen compared with the balance as of March 31, 2025. This was primarily due to an increase in property, plant and equipment of 3,824 million yen mainly arising from an increase in hospice facilities. Total liabilities as of December 31, 2025 amounted to 63,790 million yen, an increase of 8,909 million yen compared with the balance as of March 31, 2025. This was primarily due to an increase in long-term borrowings of 9,498 million yen mainly arising from proceeds from long-term borrowings designated for financing the domestic hospice construction and overseas business operations, which was partially offset by a decrease in income taxes payable of 1,124 million yen resulting from the payment of income taxes.

Total equity as of December 31, 2025 amounted to 32,194 million yen, an increase of 1,908 million yen compared with the balance as of March 31, 2025. This was primarily due to an increase in retained earnings of 1,433 million yen arising from the recording of net income attributable to CUC shareholders.

## (3) Explanation of forward-looking information such as consolidated financial results forecast

CUC has decided to leave its consolidated forecasts unchanged from those announced on April 28, 2025.

## 2. Consolidated financial statements

### (1) Consolidated statement of financial position

(Million yen)

|                               | As of March 31, 2025 | As of December 31, 2025 |
|-------------------------------|----------------------|-------------------------|
| Assets                        |                      |                         |
| Current assets                |                      |                         |
| Cash and cash equivalents     | 7,533                | 13,269                  |
| Trade and other receivables   | 12,151               | 13,457                  |
| Inventories                   | 160                  | 110                     |
| Other financial assets        | 94                   | 103                     |
| Other current assets          | 582                  | 757                     |
| Total current assets          | 20,520               | 27,696                  |
| Non-current assets            |                      |                         |
| Property, plant and equipment | 18,830               | 22,654                  |
| Right-of-use assets           | 19,401               | 19,442                  |
| Goodwill                      | 13,665               | 14,222                  |
| Intangible assets             | 4,306                | 4,148                   |
| Investment property           | 4,327                | 3,801                   |
| Deferred tax assets           | 893                  | 959                     |
| Other financial assets        | 3,167                | 2,995                   |
| Other non-current assets      | 57                   | 67                      |
| Total non-current assets      | 64,647               | 68,288                  |
| Total assets                  | 85,167               | 95,984                  |

(Million yen)

|   | As of March 31, 2025 | As of December 31, 2025 |
|---|----------------------|-------------------------|
| Liabilities and equity                  |                      |                         |
| Liabilities                             |                      |                         |
| Current liabilities                     |                      |                         |
| Trade and other payables                | 4,314                | 4,134                   |
| Borrowings                              | 2,812                | 3,397                   |
| Lease liabilities                       | 2,769                | 2,997                   |
| Deposits received                       | 692                  | 738                     |
| Income taxes payable                    | 1,233                | 109                     |
| Contract liabilities                    | 3                    | 12                      |
| Other current liabilities               | 1,622                | 1,869                   |
| Total current liabilities               | 13,446               | 13,256                  |
| Non-current liabilities                 |                      |                         |
| Borrowings                              | 20,653               | 29,565                  |
| Lease liabilities                       | 17,310               | 17,219                  |
| Retirement benefit liability            | 268                  | 344                     |
| Deferred tax liabilities                | 1,478                | 1,687                   |
| Other financial liabilities             | 893                  | 685                     |
| Other non-current liabilities           | 833                  | 1,034                   |
| Total non-current liabilities           | 41,435               | 50,534                  |
| Total liabilities                       | 54,881               | 63,790                  |
| Equity                                  |                      |                         |
| Share capital                           | 7,669                | 7,669                   |
| Capital surplus                         | 7,820                | 7,818                   |
| Retained earnings                       | 13,457               | 14,889                  |
| Treasury shares                         | (0)                  | (0)                     |
| Other components of equity              | 732                  | 1,210                   |
| Equity attributable to CUC shareholders | 29,678               | 31,586                  |
| Non-controlling interests               | 608                  | 608                     |
| Total equity                            | 30,286               | 32,194                  |
| Total liabilities and equity            | 85,167               | 95,984                  |

(2) Consolidated statement of income and comprehensive income

Consolidated statement of income

(Million yen)

|  | Nine months ended<br>December 31, 2024 | Nine months ended<br>December 31, 2025 |
|--|--|--|
| Revenue                                      | 34,562                                 | 40,170                                 |
| Cost of sales                                | 17,335                                 | 21,558                                 |
| Gross profit                                 | 17,227                                 | 18,612                                 |
| Selling, general and administrative expenses | 12,823                                 | 16,061                                 |
| Other income                                 | 264                                    | 678                                    |
| Other expenses                               | 92                                     | 48                                     |
| Operating profit                             | 4,576                                  | 3,181                                  |
| Finance income                               | 339                                    | 43                                     |
| Finance costs                                | 379                                    | 526                                    |
| Profit before taxes                          | 4,536                                  | 2,699                                  |
| Income tax expense                           | 1,814                                  | 1,328                                  |
| Net income                                   | 2,722                                  | 1,371                                  |
| Net income attributable to                   |  |  |
| CUC shareholders                             | 2,770                                  | 1,433                                  |
| Non-controlling interests                    | (48)                                   | (61)                                   |
| Net income                                   | 2,722                                  | 1,371                                  |
| Earnings per share                           |  |  |
| Basic earnings per share                     | 94.50                                  | 48.87                                  |
| Diluted earnings per share                   | 94.50                                  | 48.87                                  |

Consolidated statement of comprehensive income

(Million yen)

|  | Nine months ended<br>December 31, 2024 | Nine months ended<br>December 31, 2025 |
|--|--|--|
| Net income   | 2,722                                  | 1,371                                  |
| Other comprehensive income   |  |  |
| Items that will not be reclassified to profit or loss  |  |  |
| Net change in fair value of equity instruments designated<br>as measured at fair value through other comprehensive<br>income | (448)                                  | (165)                                  |
| Total of items that will not be reclassified to profit or loss   | (448)                                  | (165)                                  |
| Items that may be reclassified to profit or loss   |  |  |
| Exchange differences on translation of foreign<br>operations   | 131                                    | 575                                    |
| Total of items that may be reclassified to profit or loss  | 131                                    | 575                                    |
| Other comprehensive income, net of tax   | (318)                                  | 410                                    |
| Comprehensive income   | <u>2,404</u>                           | <u>1,781</u>                           |
| Comprehensive income attributable to   |  |  |
| CUC shareholders   | 2,477                                  | 1,792                                  |
| Non-controlling interests  | (72)                                   | (11)                                   |
| Comprehensive income   | <u>2,404</u>                           | <u>1,781</u>                           |

(3) Consolidated statement of changes in equity  
(Nine months ended December 31, 2024)

(Million yen)

|  | Equity attributable to CUC shareholders |                 |                   |                 | Other components of equity                                |                          |
|--|---|-----------------|-------------------|-----------------|---|--------------------------|
|  | Share capital                           | Capital surplus | Retained earnings | Treasury shares | Exchange differences on translation of foreign operations | Share acquisition rights |
| As of April 1, 2024  | 7,669                                   | 7,761           | 10,307            | (0)             | 589   | 80                       |
| Net income   | -                                       | -               | 2,770             | -               | -   | -                        |
| Other comprehensive income                                 | -                                       | -               | -                 | -               | 155   | -                        |
| Comprehensive income                                       | -                                       | -               | 2,770             | -               | 155   | -                        |
| Purchase of treasury shares                                | -                                       | -               | -                 | (0)             | -   | -                        |
| Issuance of share acquisition rights                       | -                                       | -               | -                 | -               | -   | 7                        |
| Share-based payment transactions                           | -                                       | 59              | -                 | -               | -   | 40                       |
| Contribution due to the establishment of a subsidiary      | -                                       | -               | -                 | -               | -   | -                        |
| Changes accompanying the loss of control over a subsidiary | -                                       | -               | -                 | -               | -   | -                        |
| Transactions with non-controlling interests                | -                                       | -               | -                 | -               | -   | -                        |
| Total transactions with shareholders                       | -                                       | 59              | -                 | (0)             | -   | 47                       |
| As of December 31, 2024                                    | 7,669                                   | 7,820           | 13,078            | (0)             | 744   | 127                      |

|  | Equity attributable to CUC shareholders                                    |       |        |                           |              |
|--|--|-------|--------|---------------------------|--------------|
|  | Other components of equity   |       | Total  | Non-controlling interests | Total equity |
|  | Financial assets measured at fair value through other comprehensive income | Total |        |                           |              |
| As of April 1, 2024  | 909  | 1,578 | 27,316 | 689                       | 28,005       |
| Net income   | -  | -     | 2,770  | (48)                      | 2,722        |
| Other comprehensive income                                 | (448)  | (294) | (294)  | (24)                      | (318)        |
| Comprehensive income                                       | (448)  | (294) | 2,477  | (72)                      | 2,404        |
| Purchase of treasury shares                                | -  | -     | (0)    | -                         | (0)          |
| Issuance of share acquisition rights                       | -  | 7     | 7      | -                         | 7            |
| Share-based payment transactions                           | -  | 40    | 99     | -                         | 99           |
| Contribution due to the establishment of a subsidiary      | -  | -     | -      | -                         | -            |
| Changes accompanying the loss of control over a subsidiary | -  | -     | -      | -                         | -            |
| Transactions with non-controlling interests                | -  | -     | -      | 34                        | 34           |
| Total transactions with shareholders                       | -  | 47    | 106    | 34                        | 140          |
| As of December 31, 2024                                    | 460  | 1,331 | 29,898 | 651                       | 30,549       |

(Nine months ended December 31, 2025)

(Million yen)

|  | Equity attributable to CUC shareholders |                 |                   |                 |   |                          |
|--|---|-----------------|-------------------|-----------------|---|--------------------------|
|  | Share capital                           | Capital surplus | Retained earnings | Treasury shares | Other components of equity                                |                          |
|  |   |                 |                   |                 | Exchange differences on translation of foreign operations | Share acquisition rights |
| As of April 1, 2025  | 7,669                                   | 7,820           | 13,457            | (0)             | (35)  | 172                      |
| Net income   | -                                       | -               | 1,433             | -               | -   | -                        |
| Other comprehensive income                                 | -                                       | -               | -                 | -               | 524   | -                        |
| Comprehensive income                                       | -                                       | -               | 1,433             | -               | 524   | -                        |
| Purchase of treasury shares                                | -                                       | -               | -                 | -               | -   | -                        |
| Issuance of share acquisition rights                       | -                                       | -               | -                 | -               | -   | -                        |
| Share-based payment transactions                           | -                                       | (2)             | -                 | -               | -   | 118                      |
| Contribution due to the establishment of a subsidiary      | -                                       | -               | -                 | -               | -   | -                        |
| Changes accompanying the loss of control over a subsidiary | -                                       | -               | -                 | -               | -   | -                        |
| Transactions with non-controlling interests                | -                                       | -               | -                 | -               | -   | -                        |
| Total transactions with shareholders                       | -                                       | (2)             | -                 | -               | -   | 118                      |
| As of December 31, 2025                                    | 7,669                                   | 7,818           | 14,889            | (0)             | 489   | 291                      |

|  | Equity attributable to CUC shareholders                                    |       |        |                           |              |
|--|--|-------|--------|---------------------------|--------------|
|  | Other components of equity   |       | Total  | Non-controlling interests | Total equity |
|  | Financial assets measured at fair value through other comprehensive income | Total |        |                           |              |
| As of April 1, 2025  | 595  | 732   | 29,678 | 608                       | 30,286       |
| Net income   | -  | -     | 1,433  | (61)                      | 1,371        |
| Other comprehensive income                                 | (165)  | 359   | 359    | 50                        | 410          |
| Comprehensive income                                       | (165)  | 359   | 1,792  | (11)                      | 1,781        |
| Purchase of treasury shares                                | -  | -     | -      | -                         | -            |
| Issuance of share acquisition rights                       | -  | -     | -      | -                         | -            |
| Share-based payment transactions                           | -  | 118   | 116    | -                         | 116          |
| Contribution due to the establishment of a subsidiary      | -  | -     | -      | 22                        | 22           |
| Changes accompanying the loss of control over a subsidiary | -  | -     | -      | (11)                      | (11)         |
| Transactions with non-controlling interests                | -  | -     | -      | -                         | -            |
| Total transactions with shareholders                       | -  | 118   | 116    | 11                        | 127          |
| As of December 31, 2025                                    | 430  | 1,210 | 31,586 | 608                       | 32,194       |

### 3. Segment information

#### (1) Overview of reportable segment

CUC group's reportable segments are components for which separate financial information is available and regularly reviewed by the board of directors to make decisions about allocation of resources to the segments and evaluate their performance.

CUC group has four reportable segments of "Medical Institution", "Hospice", "In-home Nursing" and "Medical Care Residence".

Medical Institution segment mainly provides comprehensive management support services to medical institutions in Japan and operates podiatry and varicose vein clinics in the United States and provides management support services in Southeast Asia.

Hospice segment provides nursing and care services for patients who live in hospice facilities.

In-home Nursing segment provides nursing services for patients at their home.

Medical Care Residence segment operates nursing homes and provides regular on-demand in-home care and in-home nursing care for patients in facilities and day care services for rehabilitation, prioritizing the quality of services.

#### (2) Information about reportable segment

Revenue, profit, and other items by reportable segments are as follows.

Intersegment transaction pricing is determined based on prevailing market prices.

(Nine months ended December 31, 2024)

(Million yen)

|                               | Reportable segment  |         |                 |                        |        | Others<br>(Note 1) | Total  | Adjustment<br>(Note 2) | Consolidated |
|-------------------------------|---------------------|---------|-----------------|------------------------|--------|--------------------|--------|------------------------|--------------|
|                               | Medical Institution | Hospice | In-home Nursing | Medical Care Residence | Total  |                    |        |                        |              |
| Revenue                       |                     |         |                 |                        |        |                    |        |                        |              |
| To outside customers          | 13,194              | 10,215  | 9,254           | 1,798                  | 34,460 | 102                | 34,562 | -                      | 34,562       |
| Inter-segment revenue         | 231                 | -       | -               | -                      | 231    | -                  | 231    | (231)                  | -            |
| Total                         | 13,425              | 10,215  | 9,254           | 1,798                  | 34,691 | 102                | 34,792 | (231)                  | 34,562       |
| Segment profit (Note 3)       | 2,992               | 1,054   | 993             | 116                    | 5,155  | 56                 | 5,211  | (635)                  | 4,576        |
| Finance income                | -                   | -       | -               | -                      | -      | -                  | -      | -                      | 339          |
| Finance costs                 | -                   | -       | -               | -                      | -      | -                  | -      | -                      | 379          |
| Profit before taxes           | -                   | -       | -               | -                      | -      | -                  | -      | -                      | 4,536        |
| Net income                    | -                   | -       | -               | -                      | -      | -                  | -      | -                      | 2,722        |
| Others                        |                     |         |                 |                        |        |                    |        |                        |              |
| Depreciation and amortization | 744                 | 721     | 365             | 363                    | 2,194  | 6                  | 2,199  | -                      | 2,199        |

(Note) 1. "Others" is a business segment which is not attributable to reportable segments and includes dispensing pharmacy services and sales of ophthalmology materials and eyeglass supplies, etc.

2. "Adjustment" of (635) million yen is primarily general and administrative expense that is not attributable to reportable segments.

3. Consolidated segment profit is correspondent with operating profit in the condensed quarterly consolidated statement of income.

(Nine months ended December 31, 2025)

(Million yen)

|                                  | Reportable segment     |         |                    |                              |        | Others<br>(Note 1) | Total  | Adjustment<br>(Note 2) | Consolidated |
|----------------------------------|------------------------|---------|--------------------|------------------------------|--------|--------------------|--------|------------------------|--------------|
|                                  | Medical<br>Institution | Hospice | In-home<br>Nursing | Medical<br>Care<br>Residence | Total  |                    |        |                        |              |
| Revenue                          |                        |         |                    |                              |        |                    |        |                        |              |
| To outside customers             | 12,316                 | 12,282  | 9,769              | 5,732                        | 40,099 | 71                 | 40,170 | -                      | 40,170       |
| Inter-segment revenue            | 330                    | -       | 6                  | -                            | 336    | -                  | 336    | (336)                  | -            |
| Total                            | 12,646                 | 12,282  | 9,775              | 5,732                        | 40,435 | 71                 | 40,506 | (336)                  | 40,170       |
| Segment profit (Note 3)          | 2,424                  | 523     | 1,103              | (149)                        | 3,901  | (16)               | 3,885  | (703)                  | 3,181        |
| Finance income                   | -                      | -       | -                  | -                            | -      | -                  | -      | -                      | 43           |
| Finance costs                    | -                      | -       | -                  | -                            | -      | -                  | -      | -                      | 526          |
| Profit before taxes              | -                      | -       | -                  | -                            | -      | -                  | -      | -                      | 2,699        |
| Net income                       | -                      | -       | -                  | -                            | -      | -                  | -      | -                      | 1,371        |
| Others                           |                        |         |                    |                              |        |                    |        |                        |              |
| Depreciation and<br>amortization | 870                    | 1,073   | 387                | 1,242                        | 3,572  | 5                  | 3,577  | -                      | 3,577        |

(Note) 1. "Others" is a business segment which is not attributable to reportable segments and includes sales of ophthalmology materials and eyeglass supplies, etc.

2. "Adjustment" of (703) million yen is primarily general and administrative expense that is not attributable to reportable segments.

3. Consolidated segment profit and loss is correspondent with operating profit in the condensed quarterly consolidated statement of income.